Drug Type Biosimilar, Monoclonal antibody |
Synonyms Palivizumab Biosimilar (Neuracle Science Co., Ltd.), NS 401, NS-401 + [1] |
Target |
Mechanism Respiratory syncytial virus F protein inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Neuracle Science Co., Ltd.Startup |
Active Organization Neuracle Science Co., Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Syncytial Virus Infections | Preclinical | KR | Neuracle Science Co., Ltd.Startup | - |